Cristóbal, I.; González-Alonso, P.; Daoud, L.; Solano, E.; Torrejón, B.; Manso, R.; Madoz-Gúrpide, J.; Rojo, F.; García-Foncillas, J.
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. Mar. Drugs 2015, 13, 3276-3286.
https://doi.org/10.3390/md13063276
AMA Style
Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, Madoz-Gúrpide J, Rojo F, García-Foncillas J.
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. Marine Drugs. 2015; 13(6):3276-3286.
https://doi.org/10.3390/md13063276
Chicago/Turabian Style
Cristóbal, Ion, Paula González-Alonso, Lina Daoud, Esther Solano, Blanca Torrejón, Rebeca Manso, Juan Madoz-Gúrpide, Federico Rojo, and Jesús García-Foncillas.
2015. "Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer" Marine Drugs 13, no. 6: 3276-3286.
https://doi.org/10.3390/md13063276
APA Style
Cristóbal, I., González-Alonso, P., Daoud, L., Solano, E., Torrejón, B., Manso, R., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J.
(2015). Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. Marine Drugs, 13(6), 3276-3286.
https://doi.org/10.3390/md13063276